Plasma glucose and insulin response to two oral nutrition supplements in adults with type 2 diabetes mellitus

Maureen B Huhmann, Kristen N Smith, Sherwyn L Schwartz, Stacie K Haller, Sarah Irvin, Sarah S Cohen, Maureen B Huhmann, Kristen N Smith, Sherwyn L Schwartz, Stacie K Haller, Sarah Irvin, Sarah S Cohen

Abstract

Objective: The purpose of this clinical trial was to compare the glucose usage of two oral nutritional supplement (ONS) products and to assess whether a diabetes-specific formulation provides improved glucose stabilization and management compared with a standard formula.

Research design and methods: A total of 12 subjects with type 2 diabetes (7 males and 5 females) completed a randomized, cross-over design trial. Each subject consumed isocaloric amounts of either the standard ONS or the diabetes-specific formula ONS on different dates, 1 week apart. Glucose and insulin measures were recorded at baseline, and 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 min after the beverage was consumed and then used to calculate area under the curve (AUC) for each subject.

Results: The mean glucose AUC was lower in the diabetes-specific ONS group than in the standard group (p<0.0001), but there was not a significant difference observed for mean insulin AUC (p=0.068). A sensitivity analysis of the mean insulin AUC measures was performed by removing a potential outlier from the analysis, and this resulted in a significant difference between the groups (p=0.012). First-phase insulin measures and an insulinogenic index calculated for the beverages showed no significant differences.

Conclusions: On the basis of the results of this trial of 12 subjects, the diabetes-specific ONS appears to provide better glucose maintenance in persons with type 2 diabetes when compared to the standard formula ONS.

Trial registration number: NCT02612675.

Keywords: Nutrition; Nutritional Intervention.

Figures

Figure 1
Figure 1
Mean glucose change from baseline by treatment product. , standard ONS; diabetes-specific ONS.
Figure 2
Figure 2
Mean insulin change from baseline by treatment product. , Standard ONS; diabetes-specific ONS.

References

    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 Atlanta, GA: US. Department of Health and Human Services, 2014.
    1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977–86. 10.1056/NEJM199309303291401
    1. Franz MJ, Bantle JP, Beebe CA et al. . Nutrition principles and recommendations in diabetes. Diabetes Care 2004;27(Suppl 1):S36–46.
    1. American Diabetes Association. 4. Foundations of care: education, nutrition, physical activity, smoking cessation, psychosocial care, and immunization. Diabetes Care 2015;38(Suppl):S20–30.
    1. Evert AB, Boucher JL, Cypress M et al. . Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2013;36:3821–42.
    1. Stratton RC, Elia M. A review of reviews: a new look at the evidence for oral nutritional supplements in clinical practice. Clin Nutr Suppl 2007;2:5–23. 10.1016/j.clnu.2007.04.004
    1. Elia M, Ceriello A, Laube H et al. . Enteral nutritional support and use of diabetes-specific formulas for patients with diabetes: a systematic review and meta-analysis. Diabetes Care 2005;28:2267–79. 10.2337/diacare.28.9.2267
    1. Gannon MC, Nuttall FQ. Factors affecting interpretation of postprandial glucose and insulin areas. Diabetes Care 1987;10:759–63. 10.2337/diacare.10.6.759
    1. Yokoyama J, Someya Y, Yoshihara R et al. . Effects of high-monounsaturated fatty acid enteral formula versus high-carbohydrate enteral formula on plasma glucose concentration and insulin secretion in healthy individuals and diabetic patients. J Int Med Res 2008;36:137–46. 10.1177/147323000803600117
    1. Ceriello A, Lansink M, Rouws CH et al. . Administration of a new diabetes-specific enteral formula results in an improved 24h glucose profile in type 2 diabetic patients. Diabetes Res Clin Pract 2009;84:259–66. 10.1016/j.diabres.2009.02.013
    1. Li YX, Zeng JB, Yu K et al. . Beneficial effects of a diabetes specific formula on insulin sensitivity and free fatty acid in patients with type 2 diabetes mellitus. Chin Med J 2008;121:691–5.
    1. Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes 2013;6:327–38. 10.2147/DMSO.S51325
    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 Atlanta, GA: Centers for Disease Control and Prevention, 2014.
    1. Portillo-Sanchez P, Bril F, Maximos M et al. . High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015;100:2231–8. 10.1210/jc.2015-1966

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe